From 2016 article:

https://www.pharmavoice.com/article/2016-06-flu-vaccine/

Tim Alefantis, Ph.D., Sanofi Pasteur’s R&D lead on the second-generation vaccine program, and Sam Lee, Ph.D., project strategy for Sanofi Pasteur’s pandemic and new influenza vaccines, talk about the company’s work to develop a broadly effective influenza vaccine.

..Sanofi Pasteur is conducting preclinical research that could lead to a flu vaccine with broader protection. In March, Sanofi Pasteur announced publication of data in the Journal of Virology on a vaccine strategy that elicited a broadly reactive response against seasonal and pandemic H1N1 influenza viruses in mice. The company, along with researchers at the University of Georgia, is working on a vaccine to protect against multiple different strains of H1N1 virus at once.

..The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus came from pigs, but the virus now circulates in humans as a seasonal form of influenza.

“We intend to be able to increase the breadth of the antibody response to recognize more strains to give broader protection,” says Tim Alefantis, Ph.D., Sanofi Pasteur’s R&D lead on the second-generation vaccine program. “The term universal vaccine is definitely aspirational. People think of universal as covering all strains and potentially one vaccination for life. But that is very complex. We see this as more of an iterative approach, and we think of a broadly protective and broadly effective vaccine as something that is more achievable and still provides a significant benefit over the current standard of care but is on the path toward a universal vaccine.”

..Nine candidates based on the COBRA technology were designed and assessed as vaccines used alone, in cocktails, or in prime-boost combinations. The most effective regimens elicited the broadest hemagglutination-inhibition (HAI) response against a panel of H1N1 viruses isolated over the past 100 years, even against viruses whose sequences were not included in the design strategy.

..Sanofi Pasteur has an existing R&D collaboration agreement with the University of Georgia to further design and develop novel synthetic vaccines based on the HA protein to help protect against disease caused by seasonal influenza strains spanning several years, including drifted strains not yet in existence.

Related posts:

Tim Alefantis vaccine scientist and cousin of James A, the H1N1 virus, Bioport, and Dynport of Dyncorp. Why is the child trafficking industry and public health industry seemingly so closely connected?

COVID-19 WUHAN lab and the French Connection - Gates Foundation and Nicole Junkermann ?

Merieux Institiute is part of Sanofi Pasteur https://en.wikipedia.org/wiki/Institut_M%C3%A9rieux

MÉRIEUX FOUNDATION https://www.fondation-merieux.org/en/where-we-work/

https://www.fondation-merieux.org/en/where-we-work/haiti/ Rodolphe Mérieux Laboratory (2009) at the Institute for Infectious Diseases and Reproductive Health at the GHESKIO (Haitian Kaposi’s Sarcoma and Opportunist Infection Study Group) Centers in Port-au-Prince, member of the GABRIEL network

Gabriel Network and the Bill and Melinda Gates Foundation, 2019 : https://www.fondation-merieux.org/en/events/10th-gabriel-network-meeting/